SMAD4 and pancreatic adenocarcinoma: Both cell lines are well-defined cell lines (SW1990 contain mutant CDKN2A, KRAS, heterozygous for TP53 p.Pro191del; and COLO 357 contain mutant KRAS and SMAD4) derived from pancreatic adenocarcinoma (PDAC), showed potential tumorigenic ability in athymic nude mice and are widely used in pancreatic cancer research [40,41,42].